You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Company Profile

Bristol-Myers Squibb Co in Consumer Health

Jun 2011

Price: US$525

About this Report

About this Report


Euromonitor International's report on Bristol-Myers Squibb Co delivers a detailed strategic analysis of the company's business, examining its performance in the Vitamins and Dietary Supplements market and the global economy.

Company and market share data provide a detailed look at the financial position of Bristol-Myers Squibb Co, while in-depth qualitative analysis will help you understand the brand strategy and growth prospects of Bristol-Myers Squibb Co This report examines:

  • Company share by region and sector
  • Brand portfolio
  • New product developments
  • Marketing and distribution strategies

A detailed SWOT analysis of Bristol-Myers Squibb Co provides strategic intelligence on:

  • Strengths and weaknesses
  • Category and country opportunities for growth
  • Challenges and threats from current competition and future prospects
  • Global and regional market positions

Research You Can Trust

Euromonitor International's company profile reports are written by our Vitamins and Dietary Supplements research team, a dedicated group of analysts that knows the industry inside and out.

Buy this report to inform your planning, strategy, marketing, sales and competitor intelligence functions.

Delivery:
Reports are delivered in pdf format and can be downloaded from your online account (called My Pages) immediately after purchase.

Table of Contents

Table of Contents

Scope of the Report

Scope

Strategic Evaluation

Key company facts

Cost reductions help drive profitability

SWOT – Bristol-Myers Squibb Co

Key strategic objectives and challenges

Competitive Positioning

Bristol-Myers Squibb – failing to keep pace

Consumer health remains fragmented

Bristol-Myers Squibb sales led by analgesics

Bristol-Myers Squibb present in the right markets

Sale of key brands

Bristol-Myers must make choice

Geographic Opportunities

Disparate presence at regional level

Mixed results in the French market

VDS products to outperform in France

Experiencing share decline in China

VDS dominates consumer health growth in China

Absence from analgesics will leave company trailing

Analgesics lead growth

Product Opportunities

Bristol-Myers Squibb – conservative expansion more likely

Expand strategically in analgesics

Create umbrella brand with Theragran

Expand Tempra into new markets in child-specific health

Brand and Private Label Strategy

Consumer health portfolio in decline

Efferalgan – dependence on French market

Operations

R&D infrastructure underlines true focus

Recommendations

Key recommendations

Samples

Please update/install flash.

my pages

Want to find out more about this report?

If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!